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Case series of vaccine associated varicella zoster virus
infection in immune compromised patients.
Vaccination with attenuated varicella zoster virus (VZV)
can lead to infectious complications in immunodeﬁcient
patients. Here we report two immunocompromised patients
who developed initial or reactivated vaccine strain varicella,
leading to unique vesicular rashes involving the vaccinated
limbs, without becoming wide-spread or remaining limited
to a single dermatome.
Case 1- A 5 year old female presented with fever, jaun-
dice, epistaxis and petechiae which began 2 weeks after
receiving a second Varivax vaccination. Diagnostic testing
revealed pancytopenia and hepatitis with a peak ALT of 1712
unit/L. A liver biopsy showed diffuse portal and lobular
hepatocellular inﬂammation with prominent lymphohistio-
cytic inﬁltrate. A bone marrow aspirate and biopsy revealed
hypocellularity and hemophagocytosis. She soon developed
vesicles on her right arm and shoulder in a non-dermatomal
pattern (Figure 1). The lesions remained localized to the
entire right upper extremity, which was the site of the earlier
Varivax vaccination. A vesicle was unroofed and the ﬂuid
tested positive for VZV by PCR. Further analysis revealed the
virus to be vaccine strain varicella. She was treated with
intravenous acyclovir and the lesions crusted over 21 days
from presentation.
Case 2- A 17 month old female with Hurler Syndrome, on
day + 6 after receiving an unrelated 7/8 Human Leukocyte
Antigen matched cord blood transplant, developed a vesic-
ular rash on her right thigh ,which was the site for Varivax
vaccination 4 months prior to transplant. A lesion was
unroofed and the ﬂuid revealed VZV by PCR. Subsequent
analysis revealed the virus to be vaccine strain varicella. She
was started on treatment with intravenous acyclovir and
intravenous immunoglobulin and her lesions crusted over
within 2 weeks.
These two cases highlight unusual presentations of
vaccine strain varicella in immunocompromised patients.
Vaccine strain varicella can cause a vesicular rash in a non-
classical distribution. It is also notable that vaccine strain
virus can trigger hemophagocytic lymphohistiocytosis in
immune deﬁcient patients.Table 1
Disease (age in years) Stem cell donor/source,
HLA match
Day of WBC
engraftment
Acute/C
WAS (2) URD/marrow, 10/10 +26 Stage I
Hunter Syndrome (5) URD/marrow, 10/10 +28 None
Hurler Syndrome (1) URD/marrow, 10/10 +27 Stage 1
Sickle beta-
thalassemia (24)
mMRD/marrow8/10 +17 None
Sickle Cell (11) mMRD/marrow8/10 +16 Stage 1
gut/no
Sickle Cell (8) URD/marrow, 10/10 +18 Stage1
dateFigure 1. Entire vaccinated limb involved in a non dermatomal pattern
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The genetic lymphohematopoietic diseases have been
effectively treated and cured by performing allogeneic HCT
from a histocompatible sibling donor following a standard
conditioning regimenwith busulfan (BU), cyclophosphamide
(CY), and antithymocyte globulin, and recently with reduced
intensity conditioning (RIC) regimens. With the use of either
conventional conditioning or RIC, the biggest limitation of
these approaches is the lack of a fully HLA-matched sibling
donor. Higher risks of graft rejection and graft-versus-host
disease (GVHD) with the use of non-matched sibling donors
e including unrelated donors (URD) or mismatched related
donors (mMRD) makes these transplants high risk with high
rates of treatment related mortality (TRM). We report
preliminary results (Table 1 below) on six patients with
genetic lymphohematological disorders lacking fully
matched sibling donors whowere transplanted using a novelhronic GvHD Viral infections Outcome (length of f/up)
II skin/skin None Alive (6 yrs), off
immunosuppression (IS)
CMV Alive (5 yrs), off IS
skin/none None Alive (3 yrs), off IS
CMV Alive (3 yrs), off IS
skin, stage 1
ne
CMV, HHV-6, Adeno,
and BK
Alive (11 mo), off IS
skin/none to HHV-6 and Adeno Alive (110 days), on IS
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tional myeloablative, targeted dose of IV BU (16 doses),
reduced dose of CY (105 mg/kg), Fludarabine (FLU) 140 mg/
m2, and Alemtuzumab 52mg/m2 total pre-transplant in 3
doses. GVHD prophylaxis consisted of alemtuzumab 10mg/
m2 on Days+1 and +2, cyclosporine (or tacrolimus), and
mycophenolate mofetil. All patients engrafted and survive
without severe GVHD. The prolonged immune deﬁciency
with intensive alemtuzumab was complicated by a high risk
of viral infection, requiring both intensive antiviral prophy-
laxis and treatment. We conclude that this regimen signiﬁ-
cantly decreases immediate post-transplant morbidity,
maintains engraftment potential, and decreases the risk of
GVHD. The use of FLU and intensive alemtuzumab condi-
tioning to permit decreased CY dosing, along with post-
transplant alemtuzumab, can overcome the major obstacles
(TRM, non-engraftment, GVHD) to successful HCT for
patients with genetic diseases lacking a conventional donor.
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Background: Acute leukemias (ALL or AML) in third
complete remission (CR3), refractory relapse (RR) or induc-
tion failure (IF) have an extremely poor prognosis, with<20%
event free survival (EFS) (Gaynon, BJH, 2005; Wells, JCO,
2003). CLO, an inhibitor of DNA polymerase and ribonucle-
otide reductase, has been shown to be safe and induce
durable remissions, both in conjunction with busulfan in
poor-risk AML (Magenau et al., Blood, 2011) and with
Melphalan in poor-risk hematologic malignancies in adults
(van Besien et al, BBMT, 2012). Clo has also been found to
have signiﬁcant activity in relapsed ALL and AML (Jeha, JCO
2006, 2009) and synergy with cytarabine (Faderl, Blood,
2005). We therefore sought to determine safety, day-100
TRM, and overall survival (OS) associated with CLO, cytar-
abine and TBI followed by AlloSCT in CAYAwith poor-risk ALL
or AML.
Methods: This is a multi-center phase I/II trial of a novel
conditioning regimen of CLO (dose escalation; maximal dose
of 52mg/m2/d achieved without dose limiting toxicity) x5d,
sequential (4 hrs later) cytarabine 1000 mg/m2 x6d and TBI
(1200cGy) followed by AlloSCT from matched related or
unrelated donors in CAYA with ALL or AML in CR3, RR or IF.Patients with unrelated donors received R-ATG. GVHD
prophylaxis consisted of tacrolimus and MMF (Bhatia/Cairo,
BBMT, 2009). Kaplan-Meier method was used to determine
the probabilities of engraftment, GVHD, TRM and OS.
Results: 29 pts, median age: 11.8 yrs (1.5-21); M:F: 20:9, ALL/
AML: 26:3 (10 CR3, 3 RR, 16 IF), 10 related donors, 19 unre-
lated donors (11 BM/PBSCs, 8 UCB). Median TNC and CD34
dose was 4.51x108/kg and 4.8 x106/kg for BM/PBSCs and
4.24x107/kg and 3.4x105/kg for UCB, respectively. Probabili-
ties of neutrophil, platelet engraftment, grade II-IV aGVHD
and chronic GVHD were 100%, 93%, 45%, and 35%, respec-
tively. Probability of Day 100 TRM was only 7.6%. The prob-
ability of relapse was 27% (CI95: 4-59%). Probability of 1-yr
PFS and OS were 52% (CI95: 30-70%), and 46% (CI95: 26-64%)
respectively.
Conclusions: These updated results suggest that this novel
conditioning regimen followed by AlloSCT is safe and well
tolerated in CAYA with very poor-risk ALL or AML with CLO
dose 52 mg/m2. Our results also continue to be encouraging
with respect to a low risk of day 100 TRM and leukemic
relapse rate associated with this conditioning regimen in this
poor-risk population. This approach should be considered in
better risk patients with ALL/AML who require AlloSCT.279
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Overview: pBKV (10,000 copies/ml) after kidney transplant
is associated with kidney injury. We hypothesized that pBKV
contributes to lower day 100 estimated kidney function
(eGFR) post-SCT.
Methods: Retrospective cohort analysis of 100 SCT recipients
prospectively enrolled to study thrombotic microangiopathy
(TMA). Plasma BK PCR testing was performed for hematuria
or elevated creatinine (creat) or on stored samples in those
with no clinical indication. We included allogeneic SCTs with
1 BK plasma PCR from each of day: 0-14, 15-85, and
10014. The outcome was day 100 eGFR using serum cys-
tatin C (cysC, muscle mass-independent eGFR) and creat.
pBKV was deﬁned as 4 consecutive weekly PCRs 10,000
copies/ml. We tested associations between pBKV and clinical
data, laboratory results, and medication exposures (coded
yes/no in ﬁrst 100 days). Multivariate regression assessed
eGFR, pBKV, and covariates with a univariate P < .2.
Results: Of 72 included subjects, 7 (10%) had pBKV and 65
(90%) did not: 7/65 had transient BKV 10,000 copies/ml on
a median of 2 measures. Selected univariate risk factors for
pBKV are shown in the Table 1. There was no difference in
age, sex, diagnosis, pre-SCT nuclear GFR, total body irradia-
tion, acute GVHD, steroid prophylaxis, cyclosporine level,
VOD, grade 2 cystitis, CMV, adenoviremia, or dialysis. By
univariate analyses, the pBKV group had signiﬁcantly lower
day 100 cysC, but not creat-based eGFR (Table 1) and more
likely received cidofovir (P < .0001). On multivariable anal-
yses, T-cell modulating antibody therapy trended (P ¼ .13)
towards an associationwith pBKV. pBKVwas associated with
